Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 6/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.55 |
| ▸ | ALB | P02768 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19884474 | 1.00 | TK1 (0.61) | TK1POLBRNASE1ALBPKM | |
| SCHEMBL14537834 | 0.92 | TK1 (0.57) | TK1POLBRNASE1 | |
| SCHEMBL12015132 | 0.92 | TK1 (0.57) | TK1POLBRNASE1 | |
| SCHEMBL12087554 | 0.92 | TK1 (0.57) | TK1POLBRNASE1 | |
| SCHEMBL16587617 | 0.91 | TK1 (0.59) | TK1POLBRNASE1ALBPKM | |
| SCHEMBL17589248 | 0.91 | TK1 (0.57) | TK1RNASE1ALBPKMLMNA | |
| SCHEMBL19884506 | 0.91 | TK1 (0.57) | TK1POLBALBPKMLMNA | |
| SCHEMBL8428685 | 0.91 | TK1 (0.67) | TK1RNASE1ALBPKMLMNA | |
| SCHEMBL14546727 | 0.91 | TK1 (0.67) | TK1RNASE1ALBPKMLMNA | |
| SCHEMBL887983 | 0.91 | TK1 (0.67) | TK1RNASE1ALBPKMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200407394-A1 | THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407394-A1 | THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA | G6PC1, GAA, GBA3 | TK1 534/4885POLB 242/4885RNASE1 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.